136 related articles for article (PubMed ID: 14605917)
1. Intravascular lymphoma presenting as telangectasias: response to rituximab and combination chemotherapy.
Weichert G; Martinka M; Rivers JK
J Cutan Med Surg; 2003; 7(6):460-3. PubMed ID: 14605917
[TBL] [Abstract][Full Text] [Related]
2. Intravascular large B-Cell lymphoma with bone marrow involvement and superior sagittal sinus thrombosis: report of a case successfully treated with a CHOP/rituximab combination regimen.
Jardin F; Callonnec F; Contentin N; Picquenot JM; Gueit I; Héron F; Bastard C; Tilly H
Clin Lymphoma; 2005 Jun; 6(1):46-9. PubMed ID: 15989707
[TBL] [Abstract][Full Text] [Related]
3. [Intravascular lymphoma: two case reports demonstrating the heterogeneity of the disease].
Satzger I; Völker B; Kofahl-Krause D; Ganser A; Kapp A; Gutzmer R
Hautarzt; 2009 Feb; 60(2):131-6. PubMed ID: 18654750
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment of diffuse large B-cell non-hodgkin lymphoma with modified CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy and rituximab in a patient with Nijmegen syndrome.
Dumic M; Radman I; Krnic N; Nola M; Kusec R; Begovic D; Labar B; Rados M
Clin Lymphoma Myeloma; 2007 Nov; 7(9):590-3. PubMed ID: 18186968
[TBL] [Abstract][Full Text] [Related]
5. The rapidly expanding role of rituximab in the treatment of aggressive B-cell lymphoma.
Cooper D
Cancer J; 2002; 8(5):364-6. PubMed ID: 12416891
[No Abstract] [Full Text] [Related]
6. The role of rituximab and chemotherapy in aggressive B-cell lymphoma: a preliminary report of dose-adjusted EPOCH-R.
Wilson WH; Gutierrez M; O'Connor P; Frankel S; Jaffe E; Chabner BA; Grossbard ML
Semin Oncol; 2002 Feb; 29(1 Suppl 2):41-7. PubMed ID: 11842388
[TBL] [Abstract][Full Text] [Related]
7. Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.
Vose JM; Link BK; Grossbard ML; Czuczman M; Grillo-Lopez A; Fisher RI
Leuk Lymphoma; 2005 Nov; 46(11):1569-73. PubMed ID: 16236611
[TBL] [Abstract][Full Text] [Related]
8. Aggressive lymphoma: improving treatment outcome with rituximab.
Coiffier B; Pfreundschuh M; Stahel R; Vose J; Zinzani PL
Anticancer Drugs; 2002 Nov; 13 Suppl 2():S43-50. PubMed ID: 12710590
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment of gastrointestinal follicular lymphoma with rituxan and combination chemotherapy.
Al-Salman J; Salib H; Boonswang P
Med Oncol; 2001; 18(4):277-83. PubMed ID: 11918454
[TBL] [Abstract][Full Text] [Related]
10. [Fever and maculopapular exanthema as first manifestation of lymphoma].
Fernández Fernández FJ; Puerta Louro R; González Vázquez L; Soto Ríos C; de la Fuente Aguado J
An Med Interna; 2007 Apr; 24(4):204-5. PubMed ID: 17882768
[No Abstract] [Full Text] [Related]
11. Remarkable remission of a follicular lymphoma treated with rituximab and polychemotherapy (CHOP).
Schmook T; Stockfleth E; Lischner S; Gahn B; Christophers E; Hauschild A
Clin Exp Dermatol; 2003 Jan; 28(1):31-3. PubMed ID: 12558625
[TBL] [Abstract][Full Text] [Related]
12. Magnetic resonance imaging of primary cardiac lymphoma.
Khuddus MA; Schmalfuss CM; Aranda JM; Pauly DF
Clin Cardiol; 2007 Mar; 30(3):144-5. PubMed ID: 17385706
[No Abstract] [Full Text] [Related]
13. Low incidence of pneumocystis pneumonia utilizing PCR-based diagnosis in patients with B-cell lymphoma receiving rituximab-containing combination chemotherapy.
Barreto JN; Ice LL; Thompson CA; Tosh PK; Osmon DR; Dierkhising RA; Plevak MF; Limper AH
Am J Hematol; 2016 Nov; 91(11):1113-1117. PubMed ID: 27472910
[TBL] [Abstract][Full Text] [Related]
14. Primary effusion lymphoma (PEL) revisited: a hematologist's perspective.
Desai S; Freeman NJ
Clin Adv Hematol Oncol; 2004 Jan; 2(1):60-1. PubMed ID: 16163162
[No Abstract] [Full Text] [Related]
15. [Intravascular lymphoma revealed by generalized arborescent telangiectasia and repeated venous thrombosis].
Vercambre-Darras S; Mortier L; Lambert M; Delattre C; Gaxotte V; Morell-Dubois S; Paccou J; Terriou L; Morschhauser F; Piette F
Ann Dermatol Venereol; 2008 May; 135(5):397-401. PubMed ID: 18457728
[TBL] [Abstract][Full Text] [Related]
16. Treatment of aggressive non-Hodgkin's lymphoma: a north American perspective.
Sehn LH; Connors JM
Oncology (Williston Park); 2005 Apr; 19(4 Suppl 1):26-34. PubMed ID: 15934515
[TBL] [Abstract][Full Text] [Related]
17. Intravascular lymphoma presenting with cauda equina syndrome: treated with CHOP and rituxan.
Davis TS
Leuk Lymphoma; 2003 May; 44(5):887-8. PubMed ID: 12802932
[No Abstract] [Full Text] [Related]
18. Combination of rituximab, cyclophosphamide, and vincristine induces complete hematologic remission of splenic marginal zone lymphoma.
Arcaini L; Orlandi E; Scotti M; Brusamolino E; Passamonti F; Burcheri S; Colombo N; Vanelli L; Sbalzarini G; Lazzarino M
Clin Lymphoma; 2004 Mar; 4(4):250-2. PubMed ID: 15072617
[TBL] [Abstract][Full Text] [Related]
19. Three cases of Pneumocystis jirovecii pneumonia (PCP) during first-line treatment with rituximab in combination with CHOP-14 for aggressive B-cell non-Hodgkin's lymphoma.
Venhuizen AC; Hustinx WN; van Houte AJ; Veth G; van der Griend R
Eur J Haematol; 2008 Mar; 80(3):275-6. PubMed ID: 18005387
[No Abstract] [Full Text] [Related]
20. Rituximab combined with CHOP for successful treatment of aggressive recurrent, pediatric B-cell large cell non-Hodgkin's lymphoma.
Jetsrisuparb A; Wiangnon S; Komvilaisak P; Kularbkaew C; Yutanawiboonchai W; Mairieng E
J Pediatr Hematol Oncol; 2005 Apr; 27(4):223-6. PubMed ID: 15838396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
